Atomwise’s Post

In 1923, Otto Heinrich Warburg discovered that cancer cells primarily metabolize glucose by fermentation and suggested in later writings that the disruption of cancer metabolism can selectively target tumor cells and is theoretically both a strategy to fundamentally solve the malignant transformation of tumors by prevention and also may be useful in the treatment of cancer. “Now, after many years of clinical research on anti-tumor strategies for oncogenes fell into difficulties, the metabolic mode of tumor cells has attracted people's attention again. Anti-cancer drugs based on Warburg effect have gradually become a hot spot in tumor research.” Exhaustive review is worth reading for summary of latest articles on every aspect of the Warburg effect 100 years after Warburg’s famous discovery. #warburgeffect2024 #p53 #circularrna #fermentationandcancer #mitochondrialdysfunction #ottowarburg

In the exciting world of drug discovery, protein degradation is making headlines! Imagine targeting cancer not just by inhibiting troublesome proteins but by kicking them out of the cell entirely. That’s the innovative promise of targeted protein degradation (TPD). The recent article dives deep into how TPD is revolutionizing cancer treatment, with a special focus on Cyclin-dependent kinase 2 (CDK2). CDK2 is like that unwanted guest at the party, driving cancer cell proliferation. TPD steps in as the ultimate bouncer, escorting CDK2 out of the cell, potentially offering a more effective and less resistance-prone approach than traditional therapies. From bridging CDK2 to E3 ubiquitin ligases for its degradation to exploring a wide range of oncogenic targets, TPD strategies are shaping up to be the Swiss Army knife of precision oncology. While there are challenges—like ensuring high specificity and overcoming resistance—ongoing research is paving the way for next-gen cancer therapies. For those intrigued by the latest in protein degradation, this resource is a must-read! Dive in, stay informed, and get ready to be amazed by what the future holds. #DrugDiscovery #ProteinDegradation #CancerResearch #Oncology #PrecisionMedicine #NextGenTherapies #ScientificInnovation

Researchers propose a novel #CRISPRCas9 approach that targets passenger single nucleotide variants (SNVs) in genes essential for cancer cell survival, expanding options for cancer therapeutics.   Traditional CRISPR targeting of oncogenic hotspot mutations is limited by their low prevalence in tumours. To broaden available targets, passenger mutations, which do not directly contribute to cancer progression but arise due to genetic instability in cancer cells, are targeted. CRISPR/Cas9 is utilised to cleave essential or haploinsufficient genes in passenger SNV regions, selectively eliminating cancer cells without affecting normal cells.    Approximately 44.8% of solid cancer patients are potentially eligible for this approach, a significant increase compared to the 14.4% with CRISPR/Cas9-applicable oncogenic hotspot mutations. This shows promise in expanding the spectrum of target mutations and increasing the eligible patient population for CRISPR #cancer therapy.   Read the full paper in Nature Portfolio: https://shorturl.at/iCGP3 

#transcript Oren Gilad, President and CEO of Aprea Therapeutics, focused on the DNA damage response pathway, specifically targeting the ATR protein. ATR is a master regulator of DNA replication and is hyperactive in cancer cells, making it a potential Achilles heel for cancer therapy. By inhibiting ATR, cancer cells can be selectively targeted, while normal cells can tolerate lower levels of ATR activity. Synthetic lethality is applied when two genetic mutations are combined, leading to cell death, specifically in cancer cells. Aprea is conducting clinical trials for their targeted treatments, focusing on solid tumors with defined genetic mutations. aprea.com https://lnkd.in/gwu8duCt

Out now! Andrea Manrique Rincón and the team led by Anneliese (Annie) Speak created an in vitro model of T cell exhaustion to help develop cancer immunotherapies. New, revolutionary cancer therapies boost the immune system to fight cancer cells, but this is hindered by T cell exhaustion, and treatments don't work for all patients. The ability to study these T cells and find ways to reinvigorate them is key to improving cancer immunotherapies. https://lnkd.in/erBPGmp3

Genialis And Pancreatic Cancer Action Network Partner To Validate RNA Biomarker For Pancreatic Cancer Learn more & get our take 👇 https://lnkd.in/g-maVfKs “Pancreatic cancer is a tough disease with few treatment options, and currently the 5-year survival rate is 13 percent. By partnering with Genialis, we will lever the data from PanCAN’s Know Your Tumor precision medicine service to further validate Genialis krasID biomarker performance in pancreatic cancer,” — Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer at PanCAN “The RAS gene family is the original white whale of cancer drug targets. Since the discovery of RAS genes and their role in promoting cancer over 40 years ago, patients, physicians, and cancer researchers have been on the hunt for a safe and effective drug against this behemoth. Yet, there are still limited treatment options,” — Rafael Rosengarten, Ph.D., CEO at Genialis #cancer #RNA #SoHCNews

Insights from a recent review article titled "Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines," published in *Gastroenterology Review*. The article dives into the role of regulated cell death, particularly ferroptosis, as a potential therapeutic target in cancer treatment. By utilizing CRISPR/Cas-9 genome editing, the researchers explore how manipulating ferroptotic pathways could overcome chemoresistance in colorectal cancer cells. Key takeaways include: - Ferroptosis: A form of regulated cell death dependent on iron and characterized by lipid peroxidation, presenting new opportunities for targeted cancer therapy. - CRISPR/Cas-9: A powerful tool in editing genes to induce or suppress ferroptosis, providing a potential pathway to combat cancer resistance. This research opens doors to novel therapies that could significantly impact the future of colorectal cancer treatment. Eager to see how these developments progress. #CancerResearch #CRISPR #ColorectalCancer

Impressive results of Celularity releasing In vivo data for their genetically modified allogeneic cell therapy, PT-CD16. The therapy was obtained from circulating T cells in the human placenta, targeting HER2-positive cancer. Achieving over 60% transduction efficiency, PT-CD16VS demonstrated significant cytotoxicity against NCI-N87 cancer cells at low Eratios and proliferated notably after 48 hours. Importantly, it exhibited no cytotoxicity against cells with low HER2 expression, ensuring specificity. In vivo tests in NSG mice models further validated its efficacy, significantly reducing tumor volumes and showing Trastuzumab-dependent tumor infiltration. These findings underline PT-CD16VS's potential for precise, effective cancer treatment with minimal off-target effects. Credit : link to AACR Abstract - https://lnkd.in/eki6fKTR and original video posted by Dr. Adrian Kilcoyne

Advance Your Prostate Cancer Treatment Pipeline with Our PSMA Nanobodies Prostate-specific membrane antigen (PSMA) is an ideal target for cancer therapies due to its high expression in prostate cancer cells and other solid tumors. Biocytogen leverages our proprietary RenMab® and RenNano® mice to develop fully human antibodies targeting PSMA, along with other promising assets like TSPAN8, CDCP1, and Nectin-4 antibodies. These innovative molecules are designed to advance drug development for prostate cancer and beyond. Discover how Biocytogen's cutting-edge technologies can accelerate your pipeline. #ProstateCancer #PSMAnanobodies #DrugDiscovery #Biocytogen #BiotechInnovation #CancerResearch

Hormone receptors - like estrogen receptor, progesterone receptor, and androgen receptor - are cancer markers that are powerful biomarkers used to understand the tumor environment and factors that might be contributing to cancer growth. Explore our catalog of oncology antibodies to find antibodies to these receptors and more. #cancerresearch #cancerbiology #oncologyresearch #antibodyresearch #monoclonalantibodies #polyclonalantibodies #labreagents #biotechsolutions https://lnkd.in/gqtRNfje